Company Overview of Sandoz International GmbH
Sandoz International GmbH develops, manufactures, and markets generic pharmaceutical products. It offers biosimilar, oncology injectable, respiratory, anti-infective, and biotechnological products, as well as medicines for various therapeutic areas, such as cardiovascular systems, central nervous systems, alimentary tracts and metabolisms, antineoplastic and immunomodulation agents, respiratory systems, and blood and blood forming organs. The company also offers drugs for suppressing recurrence of ischemic cerebrovascular disorder, lowering cholesterol, and preventing organ transplant rejection (kidney, liver, heart, lung, pancreas, and small intestine). It serves customers in Germany and in...
Key Executives for Sandoz International GmbH
Head of North American Operations and President of Sandoz US
Head of Legal and General Counsel
Head of Western Europe, Middle-East & Africa
Compensation as of Fiscal Year 2015.
Sandoz International GmbH Key Developments
Sandoz Launches Three New Generic Drugs in Japan
Jun 26 15
Sandoz has launched three new generic drugs, clopidogrel, tacrolimus and pitavastatin, in Japan. Clopidogrel, a generic version of Sanofi's Plavix, is used for suppression of recurrence of ischemic cerebrovascular disorder. Tacrolimus, a generic version of Astellas's PROGRAF, is used among others to prevent organ transplant rejection (kidney, liver, heart, lung, pancreas, small intestine). Pitavastatin, a generic version of Kowa's LIVALO, is used for lowering cholesterol. These will provide patients with alternative treatments and support further the penetration of generic medicines in Japan in line with the government's efforts.
Sandoz Announces US Launch of Glatopa(TM)
Jun 18 15
Sandoz announced the US launch of GlatopaTM, the first generic version of Teva's Copaxone(R) (glatiramer acetate injection) 20 mg/ml one-time-daily multiple sclerosis therapy. MS is a debilitating disease affecting about half a million individuals in the US alone; only half of those diagnosed are currently treated. Glatopa, developed in collaboration with Momenta and produced entirely in the US, is indicated for the treatment of patients with relapsing forms of MS, including those who have experienced a first clinical episode and have magnetic resonance imaging (MRI) features consistent with MS. The Sandoz service offering will include financial assistance to qualified patients, personalized injection training and 24-hour access to nurses for non-clinical questions. Fighting MS, together with other CNS disorders, is central to the Novartis mission, and Sandoz's Glatopa joins a broad MS portfolio including two approved therapies and one late-stage development compound. Approximately 16% of glatiramer acetate patients vs. 4% of those on placebo experienced a constellation of symptoms immediately after injection that included at least 2 of the following: flushing, chest pain, palpitations, anxiety, dyspnea, throat constriction, and urticaria. These symptoms generally have their onset several months after the initiation of treatment, although they may occur earlier, and a given patient may experience 1 or several episodes of these symptoms. Typically, the symptoms were transient and self-limited and did not require treatment; however, there have been reports of patients with similar symptoms who received emergency medical care. Transient chest pain was noted in 13% of glatiramer acetate patients vs. 6% of placebo patients. While some episodes of chest pain occurred in the context of the immediate post-injection reaction described above, many did not. The temporal relationship of this chest pain to an injection was not always known. The pain was transient, often unassociated with other symptoms, and appeared to have no clinical sequelae. Some patients experienced more than 1 such episode, and episodes usually began at least 1 month after the initiation of treatment.
BioQuiddity Incorporated Signs Licensing Agreement with Sandoz International GmbH
May 14 15
BioQuiddity Incorporated has signed an exclusive licensing and supply agreement with Sandoz International GmbH under which Sandoz has the right to market BioQuiddity's ready-to-use ropivacaine and propofol infusion pharmaceutical products in the US. Under the agreement, BioQuiddity is responsible for obtaining the requisite regulatory approvals and supplying the unit-dose infusion systems, and Sandoz is responsible for marketing and commercializing the products.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|